Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1929417 | 0.84 | MAPK14 (0.42) | SCN9AHTR2A | |
| SCHEMBL2292891 | 0.82 | SCN9A (0.42) | SCN9A | |
| SCHEMBL2290959 | 0.81 | TAS1R3 (0.37) | SCN9AHTR2AKAT6ATAS1R3TAS1R1 | |
| SCHEMBL3285899 | 0.81 | TAS1R3 (0.47) | HTR2ATAS1R3TAS1R1 | |
| SCHEMBL13325344 | 0.81 | TAS1R3 (0.47) | HTR2ATAS1R3TAS1R1 | |
| SCHEMBL2290146 | 0.81 | DHODH (0.43) | SCN9A | |
| SCHEMBL3304686 | 0.77 | CYP2C9 (0.39) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3306956 | 0.77 | CYP2C9 (0.39) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1928518 | 0.77 | KDM4E (0.38) | SCN9AHTR2AKAT6A | |
| SCHEMBL1929575 | 0.76 | NPC1 (0.37) | SCN9AHTR2AKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999136-B2 | Amide compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999136-B2 | Amide compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999136-B2 | Amide compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2143709-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | NAT1, AGXT, HAX1 | SCN9A 1038/4885HTR2A 4680/4885KAT6A 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.